Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.

@article{Kerkhof2016SecukinumabLS,
  title={Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.},
  author={Peter C. M. van de Kerkhof and Christopher Griffiths and K Reich and Craig L. Leonardi and Andrew Blauvelt and T-F Tsai and Yankun Gong and Jiaqing Huang and Charis Papavassilis and Todd K Fox},
  journal={Journal of the American Academy of Dermatology},
  year={2016},
  volume={75 1},
  pages={83-98.e4}
}
BACKGROUND Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe plaque psoriasis. OBJECTIVE We reviewed safety data from the secukinumab psoriasis phase II/III program. METHODS Data were pooled from 10 phase II/III secukinumab psoriasis studies. RESULTS Analysis included 3993 subjects; 3430 received secukinumab, representing 2725 subject-years (SYs) of exposure. Over 52 weeks, for secukinumab 300 mg… CONTINUE READING